Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? (Q82865841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

C E M Hollak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

G E Linthorst

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

4 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Clinical benefit of enzyme replacement therapy in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.013

10.1016/J.YMGME.2008.10.013

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19062323%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference